Next Article in Journal
Multiple Routes to Oestrogen Antagonism
Next Article in Special Issue
Neuroactive Multifunctional Tacrine Congeners with Cholinesterase, Anti-Amyloid Aggregation and Neuroprotective Properties
Previous Article in Journal
Inactivation of Anandamide Signaling: A Continuing Debate
Article Menu

Export Article

Open AccessReview
Pharmaceuticals 2010, 3(11), 3371-3416; https://doi.org/10.3390/ph3113371

Nanomedicine Faces Barriers

1
Department of Anatomy, Histology and Embryology, Innsbruck Medical University, Müllerstrasse 59, 6020 Innsbruck, Austria
2
Department of Radiology, Innsbruck Medical University, Anichstrasse 35, 6020 Innsbruck, Austria
*
Author to whom correspondence should be addressed.
Received: 31 August 2010 / Revised: 5 October 2010 / Accepted: 25 October 2010 / Published: 28 October 2010
(This article belongs to the Special Issue Neuroactive Compounds)
View Full-Text   |   Download PDF [916 KB, uploaded 28 October 2010]   |  

Abstract

Targeted nanoparticles have the potential to improve drug delivery efficiencies by more than two orders of magnitude, from the ~ 0.1% which is common today. Most pharmacologically agents on the market today are small drug molecules, which diffuse across the body’s blood-tissue barriers and distribute not only into the lesion, but into almost all organs. Drug actions in the non-lesion organs are an inescapable part of the drug delivery principle, causing “side-effects” which limit the maximally tolerable doses and result in inadequate therapy of many lesions. Nanoparticles only cross barriers by design, so side-effects are not built into their mode of operation. Delivery rates of almost 90% have been reported. This review examines the significance of these statements and checks how far they need qualification. What type of targeting is required? Is a single targeting sufficient? What new types of clinical challenge, such as immunogenicity, might attend the use of targeted nanoparticles? View Full-Text
Keywords: nanomedicine; vascular barriers; glandular tissues; central nervous tissues; transbarrier targeting; lesion-specific targeting nanomedicine; vascular barriers; glandular tissues; central nervous tissues; transbarrier targeting; lesion-specific targeting
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Debbage, P.; Thurner, G.C. Nanomedicine Faces Barriers. Pharmaceuticals 2010, 3, 3371-3416.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top